Switch theme
Sign up to access all valuation multiples
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
2009
24
LTM Revenue n/a
LTM EBITDA -$38.2M
$29.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PDS Biotechnology has a last 12-month revenue of n/a and a last 12-month EBITDA of -$38.2M.
In the most recent fiscal year, PDS Biotechnology achieved revenue of n/a and an EBITDA of -$33.8M.
PDS Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PDS Biotechnology valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$40.1M | -$33.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$40.9M | -$42.9M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PDS Biotechnology's stock price is $1.
PDS Biotechnology has current market cap of $49.0M, and EV of $29.2M.
See PDS Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.2M | $49.0M | XXX | XXX | XXX | XXX | $-1.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PDS Biotechnology has market cap of $49.0M and EV of $29.2M.
PDS Biotechnology's trades at n/a LTM EV/Revenue multiple, and -0.8x LTM EBITDA.
Analysts estimate PDS Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PDS Biotechnology and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $29.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | XXX | XXX |
| P/E | -1.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPDS Biotechnology's NTM/LTM revenue growth is n/a
PDS Biotechnology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.5M for the same period.
Over next 12 months, PDS Biotechnology's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PDS Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PDS Biotechnology and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -16% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PDS Biotechnology acquired XXX companies to date.
Last acquisition by PDS Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . PDS Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PDS Biotechnology founded? | PDS Biotechnology was founded in 2009. |
| Where is PDS Biotechnology headquartered? | PDS Biotechnology is headquartered in United States of America. |
| How many employees does PDS Biotechnology have? | As of today, PDS Biotechnology has 24 employees. |
| Who is the CEO of PDS Biotechnology? | PDS Biotechnology's CEO is Dr. Frank Bedu-Addo, PhD. |
| Is PDS Biotechnology publicy listed? | Yes, PDS Biotechnology is a public company listed on NAS. |
| What is the stock symbol of PDS Biotechnology? | PDS Biotechnology trades under PDSB ticker. |
| When did PDS Biotechnology go public? | PDS Biotechnology went public in 2015. |
| Who are competitors of PDS Biotechnology? | Similar companies to PDS Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PDS Biotechnology? | PDS Biotechnology's current market cap is $49.0M |
| What is the current EBITDA of PDS Biotechnology? | PDS Biotechnology's last 12-month EBITDA is -$38.2M. |
| What is the current EV/EBITDA multiple of PDS Biotechnology? | Current EBITDA multiple of PDS Biotechnology is -0.8x. |
| Is PDS Biotechnology profitable? | Yes, PDS Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
